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Introduction
Symptom exacerbations or relapses in schizophrenia during 
maintenance treatment often lead to inferior outcomes and 
increased hospitalization risk (Carbon and Correll, 2014; Kane, 
2013; Nasrallah and Lasser, 2006). The long-term consequences 
of relapses include increased risk of self-harm, decline in psycho-
social and occupational abilities, increasing personal and health-
care burden, social stigmatization, and progressive clinical 
deterioration (Almond et al., 2004; Kane, 2007; Thornicroft 
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Abstract
Background: Limited data are available to help identify patients with schizophrenia who are most likely to benefit from long-acting injectable 
antipsychotics.
Aim: To investigate the efficacy of long-acting injectable antipsychotic paliperidone palmitate one-month formulation for preventing relapses, 
factors influencing time to first relapse, and the effect of different antipsychotic adherence levels on time to first relapse in Chinese patients with 
schizophrenia.
Methods: This was a post-hoc analysis from an open-label, single-arm study of stable patients (Positive and Negative Syndrome Scale total score <70; 
n=367) receiving paliperidone palmitate one-month formulation at the end of an acute 13-week treatment phase, who entered a naturalistic one-
year follow-up period, either continuing with flexibly dosed paliperidone palmitate one-month formulation (75–150 mg eq.) or switching to another 
antipsychotic(s).
Results: There were 362/367 patients (age=31.4±10.75 years) included in the analysis of time to first relapse (primary outcome) and 327/362 
patients (39/327, poor antipsychotic adherence (<80%)) willing to receive antipsychotics were included in the exposure/adherence analysis. Overall, 
84.6% (95% confidence interval=79.2–88.7) patients remained relapse-free. Poor adherence during follow-up (hazard ratio=2.97, 95% confidence 
interval=1.48–5.98, p=0.002) and frequent hospitalizations in the previous year (hazard ratio=1.29, 95% confidence interval=1.02–1.62, p=0.03) 
were associated with a significant risk of shorter time to first relapse in the univariate analysis. In patients with poor adherence, ‘no use’ (hazard 
ratio=13.13, 95% confidence interval=1.33–129.96, p=0.03) and ‘interrupted use’ (hazard ratio=11.04, 95% confidence interval=1.03–118.60, 
p=0.047) of paliperidone palmitate one-month formulation (vs continued use) showed a significantly higher risk of relapse; this was not observed in 
patients with good (≥80%) antipsychotic adherence. No new safety concerns were identified.
Conclusion: Continued use of paliperidone palmitate one-month formulation/long-acting injectable antipsychotic was effective in preventing 
schizophrenia relapses, especially in patients with suboptimal antipsychotic adherence.
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et al., 2009). Thus, delaying the time to relapse and achieving 
optimal symptom control are fundamental objectives of schizo-
phrenia management that are recommended by existing clinical 
practice guidelines (Kane and Garcia-Ribera, 2009; Malla et al., 
2013).
Poor adherence (<70% to 80% of prescribed medications) or 
nonadherence to antipsychotics is recognized as one of the 
strongest risk factors for relapses in schizophrenia (Agid et al., 
2010; Ascher-Svanum et al., 2009; Kane et al., 2013; Novick 
et al., 2010). Medication discontinuations substantially increase 
the risk of relapse during the critical early intervention period 
(first 2–5 years of illness) that determine the long-term course of 
treatment outcome in schizophrenia (Birchwood et al., 1998; 
Chien et al., 2016). In a survival analysis of relapses, stopping 
antipsychotic medications was the strongest predictor of relapses, 
increasing the risk by five-fold compared with patients continu-
ing antipsychotic treatment (hazard ratio (HR) to first 
relapse=4.89, 99% confidence interval (CI)=2.49–9.60) 
(Robinson et al., 1999). Similar results were obtained in another 
study of first-episode patients with schizophrenia, where nonad-
herence to antipsychotic treatment was the only predictor of 
relapse, also increasing the relapse risk by about five-fold 
(HR=4.8, 95% CI=2.9–7.7) (Caseiro et al., 2012). Medication 
nonadherence was also the greatest risk factor associated with 
relapse (odds ratio (OR)= 4.6, 95% CI=3.4–6.2) in a one-year 
real-world study conducted in China (Xiao et al., 2015). 
Additionally, results from a survey of 1854 psychiatrists from the 
People’s Republic of China reported that nearly 56% (range: 
30–71%) of patients with schizophrenia were either partially or 
fully non-adherent to medications (Olivares et al., 2013).
The use of long-acting injectable (LAI) antipsychotics at vari-
ous stages of schizophrenia (patients with first-episode, insuffi-
cient response to oral antipsychotics, or history of relapse) has 
been shown to reduce nonadherence and subsequent episodes of 
relapses and hospitalizations (Correll et al., 2016; Heres et al., 
2014). Extensive studies have demonstrated the therapeutic effi-
cacy of paliperidone palmitate one-month formulation (PP1M), 
an atypical LAI antipsychotic (dopamine (D2) and serotonin 
(5-HT2A) receptor antagonist), along with practical advantages 
of extended durations of therapeutic plasma levels, simplified 
medication schedules, and efficient monitoring of treatment 
schedules (Agid et al., 2010; Alphs et al., 2013; Gonzalez-
Rodriguez et al., 2015; Samtani et al., 2009). Evidence for effec-
tive relapse prevention with PP1M supporting maintenance 
treatment is accrued largely from studies of non-Asian patients 
(Alphs et al., 2015; Gopal et al., 2011; Hough et al., 2010; 
McEvoy et al., 2014).
This post-hoc analysis was conducted in the one-year obser-
vational follow-up phase following the 13-week, acute treatment 
phase of a large prospective, open-label study of flexibly dosed 
PP1M in Chinese patients with acute schizophrenia showing 
unsatisfactory response to prior antipsychotics (Si et al., 2015b). 
The role of PP1M in the prevention of schizophrenia relapse over 
a one-year period among patients who continued treatment with 
PP1M or any antipsychotic (PP1M switched to other antipsy-
chotics) was explored in the follow-up phase analyses using a 
naturalistic design. Further, predictors of relapse prevention, 
including the relationship between the proportion of PP1M medi-
cation usage and time to first relapse (TFR) in patients with dif-
ferent degrees of antipsychotic adherence, was also characterized. 
Overall, the primary objective was to evaluate the impact of 
PP1M versus other antipsychotics, in preventing schizophrenia 
relapse in patients with different levels of adherence and deter-
mine factors influencing TFR.
Methods
Patients and study design
Data from an open-label, single-arm, multicenter phase 4 study 
(NCT01685931) were analyzed. The study was conducted 
between October 2012–December 2014 at 22 sites in the People’s 
Republic of China and consisted of three phases: a screening 
phase of up to seven days, a 13-week acute treatment phase, and 
a one-year observational follow-up phase that provided data for 
the current analyses.
Details of study design and primary results have been reported 
previously (Si et al., 2015b). Briefly, adults (18–65 years, inclu-
sive) with a diagnosis of acute schizophrenia based on Diagnostic 
and Statistical Manual of Mental Disorders-IV-Text Revision 
(DSM-IV-TR; American Psychiatric Association, 2000) criteria 
who lacked a satisfactory therapeutic effect to previous oral 
antipsychotic treatment (i.e. Positive and Negative Syndrome 
Scale (PANSS) total score of 70–120 at screening and baseline) 
were eligible. Major exclusion criteria were: active, non-schizo-
phrenia DSM-IV-TR axis 1 diagnosis; attempted suicide within 
12 months before screening, or at imminent risk of suicidal or 
violent behavior; risk factors for prolonged QT interval, torsades 
de pointes, or sudden death; treatment with clozapine or mono-
amine oxidase inhibitor antidepressants within one month before 
screening; use of LAI antipsychotics including PP1M (within six 
injection intervals before screening); or use of electroconvulsive 
therapy within one month before screening. For the present post-
hoc analysis, symptomatically stable patients (PANSS total score 
<70) at week 13 who continued in the follow-up phase and 
received PP1M or any antipsychotic in the first month of the 
maintenance period after the 13-week acute phase were included.
An independent ethics committee at each study center 
approved the study protocol. This study was conducted in accord-
ance with the ethical principles that have their origin in the 
Declaration of Helsinki and in accordance with International 
Conference on Harmonization’s Good Clinical Practice guide-
lines and applicable regulatory requirements. All patients pro-
vided written informed consent prior to study enrollment.
Treatments
Eligible patients received (Invega Sustenna, Janssen, Division of 
Ortho-McNeil-Janssen Pharmaceuticals, Inc.) deltoid injections 
of PP1M at a dose of 150 mg eq. of paliperidone (PP) (equal to 
234 mg of PP) on day 1 and 100 mg eq. (156 mg of PP) on day 8 
followed by a monthly maintenance flexible dose between 75–
150 mg eq. (117–234 mg of PP) of PP (deltoid or gluteal injec-
tions) during the acute 13-week treatment phase. All oral 
antipsychotics taken prior to study entry were gradually tapered 
and then withdrawn in the first two weeks after initiation of 
PP1M.
During the one-year observational follow-up phase (the focus 
of this study), patients continued PP1M injection, switched to 
other oral or LAI antipsychotics or continued without any 
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treatment, based on patient and prescriber preference/judgment. 
PP1M was provided gratis to study patients during the 13-week 
acute treatment phase; patients needed to source and pay for 
PP1M or other AP medications during the one-year observational 
follow-up phase.
Assessments
The primary endpoint of the post-hoc analysis was estimation of 
TFR during the period of analysis (30 days after a 13-week acute 
treatment phase to date of the first relapse or end of study during 
the follow-up phase). All patients who did not relapse during the 
follow-up phase were censored at end of the study. Relapse was 
defined by occurrence of one or more of the following: (a) hospi-
talization due to symptoms of schizophrenia (involuntary or vol-
untary); (b) two consecutive assessments at which PANSS total 
score was increased by 25% in patients with PANSS total scores 
>40 at baseline, or by 10 points in patients whose PANSS total 
score was ≤40 at baseline; (c) intentional self-harm or aggressive 
behavior, suicide or homicide attempts, or aggressive behavior 
with clinical significance; and (d) pre-selected baseline PANSS 
item scores (P1, P2, P3, P6, P7, and G8) of ≤3 increased to ≥5 in 
two consecutive assessments, or item scores of four at baseline 
increased to ≥6 (Hough et al., 2010).
Antipsychotic exposure and adherence. Adherence to all anti-
psychotics (any prescribed LAI antipsychotic and/or oral anti-
psychotics) was calculated as the ratio of cumulative exposure 
duration of all antipsychotics (days) to TFR (days) or time to the 
study completion/withdrawal (days) (for patients who did not 
relapse). Details of antipsychotic use were identified by prescrip-
tion. Patients treated with LAI antipsychotics were considered as 
still exposed to the drug during the interval between the last 
administration and the next regularly scheduled administration 
(for example, if patients were only treated with PP1M, the expo-
sure duration of PP1M was the date of the last injection+30 
days). Antipsychotic exposure was treated as both a continuous 
variable (percentage of time with adherence) and a categorical 
variable. For the categorical variable, patients adhering to <80% 
of all prescribed antipsychotics were classified as patients with 
poor adherence, while those adhering to ≥80% of all prescribed 
antipsychotics were considered as patients with good adherence.
Proportion of PP1M usage. The ratio of PP1M to all antipsy-
chotics was also examined as a factor influencing TFR. There-
fore, the proportion of PP1M usage was estimated to investigate 
the impact of PP1M usage as compared with other antipsychotics 
in preventing relapses. As the impact of PP1M was to be esti-
mated in patients who were receiving at least some antipsychotic 
therapy, patients exposed to antipsychotics for at least one day 
(antipsychotic adherence >0%) were included in the analysis. As 
part of the sensitivity analysis, the impact of usage of all LAI 
antipsychotics (includes PP1M and other LAI antipsychotics) on 
TFR was also investigated. The ratio of cumulative exposure 
duration of PP1M/all LAI antipsychotics (days) to cumulative 
exposure duration of all antipsychotics (days) was calculated. 
Similarly to the analysis of antipsychotic adherence, patients 
treated with LAI antipsychotics were considered as still exposed 
to the medication during the interval between the last administra-
tion and the next regularly scheduled administration. Likewise, 
the proportion of PP1M/all LAI antipsychotic usage was esti-
mated as both a continuous variable and a categorical variable. 
As a categorical variable, this parameter was divided into three 
types: (a) no use PP1M/all LAI antipsychotics (proportion of 
PP1M/all LAI antipsychotic usage=0), patients were not treated 
by PP1M/all LAI antipsychotics before relapse or the study com-
pletion/withdrawal; (b) interrupted use PP1M/all LAI antipsy-
chotics (proportion of PP1M/all LAI antipsychotic usage >0 but 
<100%), patients received at least one injection of PP1M/all LAI 
antipsychotics before relapse or the study completion/with-
drawal; (c) continued use PP1M/all LAI antipsychotics (propor-
tion of PP1M/all LAI antipsychotic usage=100%), patients 
regularly received PP1M/all LAI antipsychotic treatment before 
occurrence of relapse or the study completion/withdrawal.
Efficacy. The following efficacy measures were assessed during 
the follow-up visits conducted every three months: PANSS total 
score (range: 30–210; higher score indicates more extreme 
schizophrenia psychopathology) (Marder et al., 1997), Clinical 
Global Impressions-Severity (CGI-S) (scores range from 1= nor-
mal to 7=extreme) (Busner and Targum, 2007), Personal and 
Social Performance (PSP) scale (71–100=not more than mild 
degree of difficulty; 31–70=moderate degree of dysfunction; 
≤30=functioning so poor that the patient required intensive 
supervision) (Morosini et al., 2000), Medication Satisfaction 
Questionnaire (MSQ; scores range from 1=extremely dissatisfied 
to 7=extremely satisfied) (Gharabawi et al., 2006; Vernon et al., 
2010).
Safety. Safety evaluations included recording of treatment-
emergent adverse events (TEAEs), vital signs, laboratory values 
and electrocardiogram.
Statistical analysis
Since the exposure analysis was intended to assess the influence 
of antipsychotic adherence and usage of PP1M on TFR, only 
patients willing to take antipsychotics during the evaluation 
period (adherence to all antipsychotics >0%) were included in 
this post-hoc analysis. The primary endpoint (TFR) was esti-
mated using the Kaplan-Meier method, and descriptive statistics 
(number of relapses, number of censored patients, and median, 
25th, and 75th percentile of time to relapse, if estimable) were 
provided.
A Cox regression model was used to analyze the association 
of specific variables with TFR and HR along with 95% CI. 
Univariate association of individual variables with TFR was 
calculated separately for patients who used PP1M or all antip-
sychotics during the study period. The following covariables 
were entered in the univariate analysis: age, sex, monthly 
income, monthly income level, number of hospitalizations in 
the previous year, disease duration, adherence to all prescribed 
antipsychotics (0%, >0% to <80%, >80%), proportion of PP1M 
usage (no use, interrupted use versus continued use (reference 
group)) and MSQ, PSP, CGI-S and total PANSS scores at base-
line and endpoint during acute phase. Independent variables 
with p≤0.15 in the univariate analysis and their potential inter-
actions were examined in a stepwise screening approach to 
construct the multivariate Cox regression model. A p=0.05 
level of significance was applied to determine whether 
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variables were added or removed from the multivariate model. 
The multivariate model further explored associations in two 
subgroups separately (poor antipsychotic adherence versus 
good antipsychotic adherence).
Results
Patient disposition and characteristics
Details of patient disposition and demographics for the acute 
treatment phase are detailed in the primary study publication (Si 
et al., 2015b). Of the 477 patients who completed the acute treat-
ment phase, 367 patients who achieved PANSS<70 at week 13 
were included in the analysis of relapse (Figure 1). The percent-
age of patients using PP1M during the one-year follow-up phase 
ranged from 18.10% (57/315) to 29.01% (105/362). The number 
of patients using other LAI antipsychotics was low and ranged 
from 2.45% (9/367) to 3.59% (13/362). A total of 362 patients 
continued the study for ≥30 days after the last PP1M injection of 
the acute phase (Figure 1). The mean (standard deviation (SD)) 
patient age was 31.4 (10.75) years, with a slight preponderance 
of men (196 (54.14%)). During the one-year follow-up period, a 
majority (288 (79.59%)) of patients had good adherence (≥80%), 
39 (10.77%) patients had poor adherence (<80%) while 35 
(9.67%) refused any treatment. Thus, a total of 327 patients with 
>0% adherence to all antipsychotics were included in the Cox 
regression analysis (Table 1).
Analysis of time to first relapse
Of 367 patients who entered the one-year observational period, 
362 were included in the analysis of relapse (n=5, excluded (n=1, 
relapsed and n=4, discontinued within one month after 13-week 
phase)). A total of 45/362 (12.4%) patients relapsed during the 
one-year observational period. The estimated percentage of 
patients remaining relapse-free was 84.6% (95% CI=79.2–88.7) 
using the Kaplan-Meier method. The 25th percentile and median 
TFR (estimated time-point at which 25% or 50% (median) of 
patients experienced a relapse) could not be estimated since 
<25% patients relapsed during the observational period.
Univariate analysis. In the univariate analysis, poor antipsy-
chotic adherence (vs good) (HR=2.97, 95% CI=1.48–5.98, 
p=0.002) and number of hospitalizations in the previous one year 
(HR=1.29, 95% CI=1.02–1.62, p=0.03) were associated with a 
significantly shorter TFR both for usage of PP1M, and all LAI 
antipsychotics. Adherence to all antipsychotics, usage of PP1M 
(interrupted use vs continued use), MSQ scores of patients and 
caregivers at the baseline of the acute phase and total PANSS 
scores at baseline in the acute phase were potentially important 
contributors to TFR (p≤0.15) and thus were also included in the 
multivariate Cox regression analysis (Table 2).
Multivariate analysis. In the multivariate Cox regression analysis, 
proportion of PP1M exposure (%), adherence to all antipsychotics 
Figure 1. Patient disposition. PANSS: Positive and Negative Syndrome Scale.
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(%) and the interaction of adherence to all antipsychotics to propor-
tion of PP1M (p=0.03) and all LAI antipsychotics (p=0.04)) expo-
sure had a significant association with TFR (Table 3). The significant 
influence of this interaction on TFR, steered the multivariate analy-
sis to further determine any clinically important difference in the 
treatment effect of PP1M and all LAI antipsychotics in delaying 
TFR due to differential adherence among patients with varied LAI 
antipsychotic usage patterns. Thus, the patients were categorized as 
having good and poor adherence to antipsychotics, and the effect of 
LAI antipsychotic usage pattern on TFR was analyzed. Other vari-
ables with a significant association with TFR included: number of 
hospitalizations in the previous one year, and total PANSS score at 
baseline in the acute phase. Interaction between proportion of LAI 
antipsychotic usage (no use vs continuous use) and adherence to all 
antipsychotics (poor vs good) were also identified as relevant con-
tributors to TFR (PP1M: p=0.04; all LAI antipsychotics: p=0.06) 
(Table 3).
Stratified analysis by good versus poor adherence. In the 
largest LAI antipsychotic subgroup (all LAI antipsychotics), the 
usage pattern of LAI antipsychotics did not show any significant 
influence on TFR in patients with good antipsychotic adherence 
(Table 4). The continued use of all LAI antipsychotics (vs no use 
(log rank test: p=0.45) and interrupted use (log rank test: p=0.36) 
of all LAI antipsychotics) did not have a significant effect on 
relapse-free survival time in these patients and the Kaplan-Meier 
plots supported this finding (Figure 2(a) and (b)). However, in 
patients with poor antipsychotic adherence, the benefits of unin-
terrupted LAI antipsychotic usage were demonstrated from the 
multivariate analysis (Table 4) as well as the Kaplan-Meier plots 
(Figure 2(c) and (d)). The continued use of all LAI antipsychotics 
(vs no use (log rank test: p=0.028) and interrupted use (log rank 
test: p=0.014)) was associated with a significantly longer relapse-
free survival period in patients with poor antipsychotic 
adherence.
Regarding the use of PP1M (patients with continued or inter-
rupted use of PP1M among all LAI antipsychotics, 122/134 
(91.0%)), the findings were generally similar to those noted in 
the all LAI antipsychotic subgroup. In patients with good antip-
sychotic adherence, no use and interrupted use of PP1M were not 
associated with any significant effect on TFR, although numeri-
cally, the results indicated higher risk of relapse compared with 
continued use of PP1M (continued vs no use: HR=1.18, 95% 
CI=0.47–2.97, p=0.7308; continued vs interrupted PP1M use: 
HR=1.59, 95% CI=0.45–5.65, p=0.4709) (Table 4). Similarly, 
continued use of PP1M (vs no use (log rank test: p=0.75) and 
interrupted use (log rank test: p=0.451)) did not demonstrate sig-
nificant relapse-prevention benefit in patients with good antipsy-
chotic adherence (Figure 2(e) and (f) shows the Kaplan-Meier 
plot of time to relapse). Among patients with poor antipsychotic 
adherence, no use (HR=13.13, 95% CI=1.33–129.96, p=0.0277) 
and interrupted use (HR=11.04, 95% CI=1.03–118.60, p=0.0474) 
of PP1M were associated with a significantly increased risk of 
relapse vs continued use of PP1M (Table 4). A significantly 
longer relapse-free survival time with continued use of PP1M (vs 
no use (log rank test: p=0.035) and interrupted use (log rank test: 
p=0.016)) was observed among patients with poor antipsychotic 
adherence, suggesting the efficacy of PP1M maintenance therapy 
Table 1. Demographics and key baseline characteristics (13-week acute 
treatment phase) and medication adherence distribution and summary 
of long-acting injectable antipsychotic (LAI) antipsychotic usage (one-
year observational follow-up phase).
Characteristics Total
(n=362)
13-week acute treatment phase  
Age, mean (SD), years 31.4 (10.75)
Sex, n (%)  
Men 196 (54.14)
Body weight, mean (SD), kg 64.4 (12.56)
BMI, mean (SD), kg/m2 23.3 (3.76)
Duration of schizophrenia, mean (SD), years 4.9 (5.25)
Duration distribution of disease, n (%)  
≤5 years 237 (65.47)
>5 years 125 (34.53)
PANSS total score, mean (SD)  
Baseline 90.5 (12.04)
Week-13 acute phase 48.9 (10.22)
CGI-S score, mean (SD)  
Baseline 5.2 (0.73)
Week-13 acute phase 2.7 (0.84)
PSP score, mean (SD)  
Baseline 46.0 (13.53)
Week-13 acute phase 70.7 (8.21)
One-year observational follow-up phase  
Degree of adherence to antipsychoticsa, n 
(%)
 
0% 35 (9.7)
<80% 39 (10.8)
≥80% 288 (79.6)
LAI usageb in patients with >0% adherence, 
n (%)
n=327
PP1M  
No use 205 (62.7)
Interrupted use 35 (10.7)
Continued use 87 (26.6)
All LAIc  
No use 193 (59.0)
Interrupted use 36 (11.0)
Continued use 98 (30.0)
BMI: body mass index; CGI-S: Clinical Global Impressions-Severity; PANSS: Posi-
tive and Negative Syndrome Scale; PSP: Personal and Social Performance Scale; 
SD: standard deviation.
aAdherence to all antipsychotics (%)=exposure duration of all antipsychot-
ics (days)/time to the first relapse (days) or study completion/withdrawal 
(days)×100. For patients on LAI antipsychotics, the last dose in the acute phase 
was considered to provide continued exposure during the interval between last 
dose and the next scheduled dose. For example, the actual exposure duration for 
PP1M in this analysis was calculated as the date of last injection in the acute 
phase+30 days. Time to the first relapse was determined as the time from the 
start date to the first relapse recorded.
bThe usage of PP1M/all LAI antipsychotics was categorized according to the 
percent of PP1M/all LAI antipsychotic exposure duration in all antipsychot-
ics exposure duration during the observational follow-up phase; 0% usage was 
defined as “no use;” 0–100% usage as “interrupted use;” and 100% usage as 
“continued use.”
cPP1M and/or other LAI antipsychotics.
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Table 2. Univariate analysis of time to first relapse.
PP1M (n=327) All LAIs (n=327)
 Hazard ratio 95% CI p-Value Hazard ratio 95% CI p-Value
Adherence to all antipsychotics (%) 0.99 0.98–1.00 0.06 0.99 0.98–1.00 0.06
Adherence distribution to all antipsychotics 
(poor adherence vs good adherence)a
2.97 1.48–5.98 0.002 2.97 1.48–5.98 0.002
Usage of PP1M/all LAI antipsychotics: inter-
rupted antipsychotic use versus continued 
use
2.52 0.88–7.18 0.08 2.74 0.96–7.81 0.06
The number of hospitalizations in the previ-
ous one year (times)
1.29 1.02–1.62 0.03 1.29 1.02–1.62 0.03
MSQ scores of patients at baseline of acute 
phase
0.80 0.62–1.03 0.08 0.80 0.62–1.03 0.08
MSQ scores of caregivers at baseline of 
acute phase
0.80 0.61–1.03 0.09 0.80 0.61–1.03 0.09
Total PANSS scores at baseline in the acute 
phase
1.02 1.00–1.05 0.10 1.02 1.00–1.05 0.10
CI: confidence interval; LAI: long-acting injectable; MSQ: Medication Satisfaction Questionnaire; PANSS: Positive and Negative Syndrome Scale; PP1M: paliperidone palmi-
tate one-month formulation; PSP: Personal and Social Performance.
aPoor adherence: adherence distribution to antipsychotics, (>0 to <80%); good adherence: adherence distribution to antipsychotics, ≥80%.
Variables tested as p≤0.15 are presented. Other variables tested: proportion of PP1M/all LAI antipsychotic exposure, usage of PP1M/all LAI antipsychotics (no use vs 
continued use); sex (women vs men), age (years), monthly income (income/month; yes vs no; income levels), disease duration (years), disease duration distribution, 
MSQ scores of patients at endpoint of acute phase, MSQ scores of caregivers at endpoint of acute phase, total PSP scores at baseline and endpoint of acute phase, CGI-S 
scores at baseline and endpoint of acute phase, total PANSS scores at baseline and endpoint of acute phase.
Table 3. Multivariate Cox regression analysis of first time to relapse (day) to investigate interaction between adherence to all antipsychotic 
medications and proportion of paliperidone palmitate one-month formulation (PP1M)/all long-acting injectable (LAI) antipsychotic usage.
PP1M (n=327) All LAIs (n=327)
 Estimate SE Chi-square p-Value Estimate SE Chi-square p-Value
Model 1: variables of interest included in continuous format
Proportion of PP1M or all LAI antipsychotics exposure (%) −0.04 0.02 5.44 0.02 −0.03 0.01 5.18 0.02
Adherence to all antipsychotics (%) −0.02 0.01 10.31 0.001 −0.02 0.01 9.85 0.002
Proportion of PP1M or all LAI andtipsychotics exposure (%) 
× adherence to all antipsychotics (%)
0.0004 0.0002 4.73 0.03 0.0003 0.0002 4.08 0.04
Total PANSS scores at baseline in the acute phase 0.03 0.01 4.38 0.04 0.03 0.01 4.38 0.04
The number of hospitalizations in the previous one year 
(times)
0.34 0.14 5.80 0.02 0.33 0.14 5.47 0.02
Model 2: variables of interest included in classified format
Usage of PP1M or all LAI antipsychotics  
No use versus continued use −0.04 0.53 0.00 0.94 0.14 0.53 0.07 0.79
Interrupted use versus continued use 0.34 0.74 0.21 0.65 0.44 0.74 0.35 0.55
Adherence distribution of all antipsychotics (poor adher-
ence vs good adherence)a
−0.65 1.14 0.33 0.57 −0.51 1.14 0.21 0.65
Interaction between adherence to all antipsychotics and 
usage of PP1M or all LAI antipsychotics
 
Usage of PP1M or all LAI antipsychotics (no use vs con-
tinued use) × adherence distribution to all antipsychot-
ics (>0−80% vs ≥80%)
2.47 1.23 4.08 0.04 2.31 1.22 3.59 0.06
Usage of PP1M or all LAI antipsychotics (interrupted 
use vs continued use) × adherence distribution to all 
antipsychotics (>0−80% vs ≥80%)
1.87 1.42 1.74 0.19 1.76 1.42 1.54 0.22
The number of hospitalizations in the previous one year 
(times)
0.25 0.14 3.47 0.06 0.25 0.14 3.23 0.07
Total PANSS scores at baseline in the acute phase 0.03 0.02 3.62 0.06 0.03 0.02 3.62 0.06
PANSS: Positive and Negative Syndrome Scale; SE: standard error.
aPoor adherence: adherence distribution to antipsychotics, (>0 to <80%); good adherence: adherence distribution to antipsychotics, ≥80%.
Independent variables tested as p≤0.15 in univariate analysis were screened automatically by using stepwise methods and analyzed in the multivariate Cox regression model.
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Table 4. Multivariate Cox regression analysis of time to first relapse with usage of paliperidone palmitate one-month formulation (PP1M)/all long-
acting injectable (LAI) antipsychotics.
PP1M All LAI antipsychotics
 Hazard ratio 95% CI p-Value Hazard ratio 95% CI p-Value
Patients with poor adherence to antipsychotics (ad-
herence distribution of all antipsychotics  
(>0, <80%), n=39
 
Usage of PP1M/all LAI antipsychoticsa  
No use versus continued use 13.13 1.33–129.96 0.0277 13.37 1.37–130.14 0.0255
Interrupted use versus continued use 11.04 1.03–118.60 0.0474 11.08 1.04–118.18 0.0465
Total PANSS scores at baseline in the acute phase 1.06 1.01–1.11 0.0285 1.06 1.01–1.11 0.0299
Patients with good adherence to antipsychotics  
(adherence distribution of all antipsychotics (≥80%), 
n=288
 
Usage of PP1M/all LAI antipsychoticsb  
No use versus continued use 1.18 0.47–2.97 0.7308 1.43 0.57–3.60 0.4485
Interrupted use versus continued use 1.59 0.45–5.65 0.4709 1.74 0.49–6.18 0.3900
Total PANSS scores at baseline in the acute phase 1.01 0.98–1.05 0.3516 1.01 0.98–1.05 0.3561
CI: confidence interval; PANSS: Positive and Negative Syndrome Scale.
aPP1M: no use, n=20; continued use, n=13; interrupted use, n=6; All LAI antipsychotics: no use, 19; continued use, n=14; interrupted use, n=6.
bPP1M: no use, n=185; continued use, n=74; interrupted use, n=29; All LAI antipsychotics: no use, 174; continued use, n=84; interrupted use, n=30.
in schizophrenia. The Kaplan-Meier plots corroborated this 
observation (Figure 2(g) and (h)).
Safety
Safety was evaluated in 362 patients who continued the study for 
≥30 days after the last PP1M injection of acute phase. During the 
one-year observational period, 50 (13.8%) patients experienced 
TEAEs. The most commonly reported TEAEs (in ≥1% patients) 
were schizophrenia (2.8%), extrapyramidal disorder (1.9%), 
weight gain (1.7%), nasopharyngitis, abnormal liver function 
(1.4% each), and upper respiratory tract infection (1.1%). Only 
one patient experienced schizophrenia that led to treatment dis-
continuation, and serious TEAEs were reported in 12 (3.3%) 
patients. One death (cause unknown) was reported during the 
observational follow-up phase (Table 5).
Discussion
Prevention of symptomatic relapses during maintenance treat-
ment in schizophrenia is an important clinical outcome with sev-
eral short- and long-term benefits. In the current study in Chinese 
patients, a large number of patients who were maintained on 
antipsychotic therapy after the 13-week acute PP1M treatment 
remained relapse-free during the one-year follow-up period. This 
finding was consistent with the low relapse rates observed in the 
global PP1M study (Hough et al., 2010). Findings from the expo-
sure analysis were suggestive of variability in the effect of PP1M 
in delaying TFR. The efficacy of relapse prevention was largely 
dependent on the continuity of PP1M usage and this influence 
had a greater clinical significance in patients with suboptimal 
antipsychotic adherence.
Among the variables examined in the study, poor antipsy-
chotic adherence and higher numbers of hospitalizations in the 
previous year were significant risk factors for relapses in the uni-
variate analysis. This finding is consistent with data from prior 
studies identifying suboptimal adherence/nonadherence as one of 
the key and modifiable factors influencing symptom exacerba-
tions in patients receiving antipsychotics (Agid et al., 2010; 
Ascher-Svanum et al., 2006; Gharabawi et al., 2006; Kaplan 
et al., 2013; Nasrallah and Lasser, 2006; Robinson et al., 1999; 
Xiao et al., 2015).
Patients with suboptimal antipsychotic adherence and who 
discontinued or sporadically used PP1M/all LAI antipsychotics 
after the acute PP1M treatment period had a significantly 
increased risk of relapse risk when compared with patients who 
continued treatment with PP1M during the one-year observational 
period. The similarities in HR for no use and interrupted use of 
PP1M/all LAI antipsychotics suggest that the benefits of LAI 
antipsychotic treatment are undermined by any disruption in treat-
ment continuity. These results suggest that continued LAI antipsy-
chotic use is effective in minimizing the gap between any level of 
antipsychotic nonadherence that is greater than 20% and the asso-
ciated downstream symptomatic relapses. The convenience of 
reduced dosing frequency and protracted dosing interval with LAI 
antipsychotics offers a distinct advantage over oral antipsychotics 
in patients with antipsychotic nonadherence or partial adherence 
(Berwaerts et al., 2015; Samtani et al., 2009). In patients with 
≥80% antipsychotic adherence (oral/ PP1M and other LAI antip-
sychotics) the relapses were not influenced by the usage of PP1M 
during the one-year follow-up period. The number of patients 
with good adherence (nearly 80%) in this study was generally 
higher than those commonly observed in clinical practice. 
Potential reasons for this observation include an initial selection 
bias toward patients with greater illness insight and readiness to 
adhere to treatments (as they were part of the 13-week, acute, con-
trolled study phase), reminders to patients for their return to fol-
low-up visits, and patients’ awareness that their adherence was 
being measured during the naturalistic follow-up period.
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Figure 2. Kaplan–Meier plots for time to first relapse. (a) Relapse-free survival in patients with good adherence to antipsychotics and on continued 
use versus no use of all long-acting injectable (LAI) antipsychotics; (b) relapse-free survival in patients with good adherence to antipsychotics and 
on continued use versus interrupted use of all LAIs; (c) relapse-free survival in patients with poor adherence to antipsychotics and on continued use 
versus no use of all LAIs; (d) relapse-free survival in patients with poor adherence to antipsychotics and on continued use versus interrupted use of 
all LAIs; (e) relapse-free survival in patients with good adherence to antipsychotics and on continued use versus no use of paliperidone palmitate 
one-month formulation (PP1M); (f) relapse-free survival in patients with good adherence to antipsychotics and on continued use versus interrupted 
use of PP1M; (g) relapse-free survival in patients with poor adherence to antipsychotics and on continued use vs interrupted use of PP1M; (h) 
relapse-free survival in patients with poor adherence to antipsychotics and on continued use versus interrupted use of PP1M.
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Overall, the TEAEs reported during the one-year naturalistic 
treatment period were consistent with the known safety and toler-
ability profile of PP1M (Gopal et al., 2011; Hough et al., 2010; 
Pandina et al., 2010; Pandina et al., 2011). No new safety con-
cerns pertaining to use of LAI antipsychotics emerged. Previous 
studies of PP1M conducted in patients from the Asia-Pacific 
region have reported improvement in patients’ psychotic symp-
toms and functioning as well as reduction in schizophrenia-related 
hospitalizations during long-term PP1M maintenance treatment 
(Li et al., 2011; Li et al., 2016; Takahashi et al., 2013; Zhang et al., 
2015). These positive findings extend not only to patients with 
chronic, multi-episode illness, but also to first-episode and early 
phase patients with illness onset within the past five years (Si 
et al., 2015a; Zhang et al., 2015). In the primary 13-week clinical 
study, patients with suboptimal responses to prior oral antipsy-
chotics responded favorably to PP1M treatment, with 73% 
patients achieving the primary efficacy endpoint (≥30% improve-
ment in the PANSS total score) (Si et al., 2015b). Thus, these 
results of this study combined with observations from the primary 
study and available evidence, lend support to the potential of 
uninterrupted LAI antipsychotic treatment over time in maintain-
ing symptom remission and prevention of relapses in schizophre-
nia (Correll et al., 2016; Robinson et al., 1999).
Although the naturalistic treatment selection and observa-
tional setting of the study are more aligned with everyday clinical 
practice as compared to randomized controlled and comparative 
studies, these results should be interpreted within the context of 
certain limitations of the study. First, the open-label design may 
have introduced a potential bias affecting patient-related and 
physician-related outcomes, and the non-comparative design of 
the study may limit the interpretation of these results. Second, the 
study was designed to evaluate relapse prevention in patients 
with stable schizophrenia (following treatment with PP1M in the 
acute phase). Although this enrichment strategy minimizes the 
influence of confounding factors, it potentially limits the general-
izability of the study results. Nevertheless, the study intended to 
evaluate the potential longer-term benefits of PP1M and LAI 
antipsychotic treatment in general, and, clinically, treatment is 
continued in patients who have demonstrated acute treatment 
benefits. The assessment of adherence was based on monitoring 
of prescription practice during the one-year follow-up phase and 
did not account for potential discrepancies between prescription 
and actual use. Lastly, the effect of concomitant medications or 
non-pharmacologic interventions was neither controlled nor sys-
tematically assessed, precluding the assessment of a potential 
influence on the findings.
In summary, >30% of patients continued on LAI antipsy-
chotic therapy (of which >90% continued PP1M) during the one-
year naturalistic treatment period following acute stabilization 
with PP1M. Treatment with PP1M also showed acceptable toler-
ability during long-term disease management. The efficacy of 
uninterrupted PP1M and all LAI antipsychotics in delaying TFR 
during the follow-up period was more pronounced in patients 
with risk factors for relapse. These risk factors included, partial 
or poor antipsychotic adherence (during the one-year study 
period), a history of hospitalizations in the past year, and greater 
illness severity at the acute treatment baseline. Collectively, these 
data may assist clinicians in selecting patients who may benefit 
the most from maintenance treatment with LAI antipsychotics.
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